• Home
  • Oneliver Science Hub

Science Hub

OneLiver Science hub is a repository of information
on chronic liver disease and liver cancer, including
disease burden, early detection and treatment,
and the benefits of multidisciplinary management.

Welcome to OneLiver Science Hub


Together, let’s stop chronic liver disease and, one day, cure HCC

Around one in five people globally suffer from chronic liver disease (CLD),1 despite 90% of cases being preventable.2 This usually undetected disease silently progresses to hepatocellular carcinoma (HCC), the third leading cause of cancer death.3,4
If something doesn’t change, it is predicted that deaths from liver cancer will increase by more than 50% by 2040.3

OneLiver Science hub is a repository of information on chronic liver disease and hepatocellular carcinoma, examining the increasing burden of global disease, discussing the unmet clinical need for screening of patients at risk of HCC and the benefits of early detection, through patient prognosis by disease stage and available treatments between early and advanced disease, and finally the benefits of managing patients with a dedicated HCC MDT and the barriers and avenues to building a successful clinical team.

Our OneLiver mission is to help stop, or even reverse the disease, and our ambition is to one day cure it. Our core expertise will continue to focus on cutting-edge diagnostics and treatment. To enable greater impact, partnerships are key. We want to work together with liver specialists, researchers and patient organisations on ambitious programmes across the disease continuum to prevent progression and ultimately save lives.

Bearded older man stretching whilst looking happy, potentially suffering
from hepatocellular carcinoma.

Burden of CLD and HCC

MDT approach to HCC care

Screening, Early detection of HCC


HCC prognosis, Treatment


1. Cheemerla S. and Balakrishnan M. Clin Liver Dis (Hoboken) 2021;17:365–370.

2. Macpherson I, et al. Frontline Gastroenterol 2022;13:367–73.

3. Rumgay H, et al. J. Hepatol. 2022;77:1598–1606.

4. Sung H, et al. CA Cancer J Clin 2021;71:209–49.

5. Vogel A, et al. Ann Oncol. 2021;32(6):801–5.

6. Reig M, et al. Journal of Hepatology 2022;76:681–93.

7. Ginès P, et al. Hepatology. 2022;75(1):219–22.

8. Zhu XD, et al. Genes & Diseases 2020;7:359–69.

9. Yopp AC, et al. Ann Surg Oncol 2014;21(4):1287–95.

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.